Skip to main content
Clinical Trials/NCT05083143
NCT05083143
Completed
Not Applicable

The Impact of the COVID-19 Pandemic on Oncologic Outcomes of Testicular Cancer

Ankara Training and Research Hospital1 site in 1 country50 target enrollmentJuly 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Testicular Cancer
Sponsor
Ankara Training and Research Hospital
Enrollment
50
Locations
1
Primary Endpoint
Rate of tumor stages
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Detailed Description

The rapid spread of the 2019 coronavirus disease (COVID-19) caused by a novel betacoronavirus known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had dramatic effects on individuals and health systems around the world. Beyond those infected with SARS-CoV-2,the intense demand for limited health system resources has led to reduced capacity, rapid depletion of healthcare systems and hospitals becoming a source of virus transmission. Urology associations and reference centers have issued recommendations to inform urology care during the COVID-19 outbreak. It is essential that urologists give priority to patient safety. Potential delays in the diagnosis and treatment of urological conditions and the additional burden on healthcare resources must be balanced against the risks of exposure to COVID-19. While this situation aims to conserve healthcare resources, it has created the risk of delaying cancer treatment. As a result, the transformation of health services and the increasing interest of the public in avoiding exposure to the disease has led to a decrease in the number of hospital admissions. The effects of the pandemic on patients with testicular cancer due to a decrease in emergency room and urology clinic admissions are not clear. During theCOVID-19 outbreak, the EAU (European Association of Urology) panel of testicular cancer published an evidence-based guideline. According to this guideline, four priority groups were formed and a certain period of delaying treatment was defined for patients in each group according to their priorities.

Registry
clinicaltrials.gov
Start Date
July 1, 2021
End Date
March 25, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Ankara Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ali Kaan Yildiz

Principal Investigator

Ankara Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with testicular cancer in the urology clinic.

Exclusion Criteria

  • Previous history of genitourinary system tumor
  • Previous history of radiotherapy or chemotherapy

Outcomes

Primary Outcomes

Rate of tumor stages

Time Frame: 2 month

Rate of tumor stages in patients who diagnosed with testicular cancer

Study Sites (1)

Loading locations...

Similar Trials